Katabi Maha — SEC Form 4 filings
SEC reporting owner CIK 1720685. 6 Form 4 filings on record with FilingPulse; latest filed 2025-05-16.
Transaction summary — filings shown
Covers all 6 filings on record, filed 2024-02-01 to 2025-05-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 161,290 shares, $4,999,990 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 6 legs across 1 filing — 834,459 shares, $34,099,583 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 6.
- Largest priced transaction: sale of 413,450 shares @ $40.51 ($16,748,860) in Vera Therapeutics, Inc., filed 2024-03-25.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | Director | 4 | 1 leg · 161,290 sh · $4,999,990 | 6 legs · 834,459 sh · $34,099,583 | 2 |
| RayzeBio, Inc. (RYZB) | Director | 1 | — | — | 3 |
| Aerovate Therapeutics, Inc. (AVTE) | Director, 10% owner | 1 | — | — | 1 |
Form 4 filings — Katabi Maha
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-05-16 | 4 | Vera Therapeutics, Inc. (VERA) | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Aerovate Therapeutics, Inc. (AVTE) | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-05-17 | 4 | Vera Therapeutics, Inc. (VERA) | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2024-03-25 | 4 | Vera Therapeutics, Inc. (VERA) | Sale (S): 32,756 @ $43 · Sale (S): 21,918 @ $44 · Sale (S): 12,617 @ $45.52 · Sale (S): 13,718 @ $46.18 · Sale (S): 413,450 @ $40.51 · Sale (S): 340,000 @ $40.50 | EDGAR |
| 2024-02-27 | 4 | RayzeBio, Inc. (RYZB) | Disposition to issuer (D): 1,209,764 @ $62.50 · Disposition to issuer (D): 1,209,764 @ $62.50 · Disposition to issuer (D): 18,235 (derivative) | EDGAR |
| 2024-02-01 | 4 | Vera Therapeutics, Inc. (VERA) | Purchase (P): 161,290 @ $31 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1720685 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →